Wuhan Keqian BiologyLtd Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Wuhan Keqian BiologyLtd has been growing earnings at an average annual rate of 1.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 9.6% per year. Wuhan Keqian BiologyLtd's return on equity is 7.7%, and it has net margins of 33.2%.
Belangrijke informatie
1.4%
Groei van de winst
-3.5%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 10.9% |
| Inkomstengroei | 9.6% |
| Rendement op eigen vermogen | 7.7% |
| Nettomarge | 33.2% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
The Market Lifts Wuhan Keqian Biology Co.,Ltd (SHSE:688526) Shares 38% But It Can Do More
Oct 09
These 4 Measures Indicate That Wuhan Keqian BiologyLtd (SHSE:688526) Is Using Debt Reasonably Well
Sep 26Investors Continue Waiting On Sidelines For Wuhan Keqian Biology Co.,Ltd (SHSE:688526)
Aug 20We Think Wuhan Keqian BiologyLtd (SHSE:688526) Can Stay On Top Of Its Debt
Jun 26Wuhan Keqian Biology Co.,Ltd (SHSE:688526) Stock Rockets 25% But Many Are Still Ignoring The Company
Apr 08Analysts Are More Bearish On Wuhan Keqian Biology Co.,Ltd (SHSE:688526) Than They Used To Be
Apr 05Earnings Miss: Wuhan Keqian Biology Co.,Ltd Missed EPS By 25% And Analysts Are Revising Their Forecasts
Apr 03Wuhan Keqian BiologyLtd (SHSE:688526) Has A Rock Solid Balance Sheet
Mar 20Opbrengsten en kosten
Hoe Wuhan Keqian BiologyLtd geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 902 | 299 | 237 | 85 |
| 30 Jun 24 | 933 | 309 | 270 | 85 |
| 31 Mar 24 | 989 | 348 | 281 | 87 |
| 31 Dec 23 | 1,064 | 396 | 298 | 89 |
| 30 Sep 23 | 1,142 | 484 | 259 | 100 |
| 30 Jun 23 | 1,139 | 490 | 252 | 100 |
| 31 Mar 23 | 1,078 | 454 | 253 | 100 |
| 31 Dec 22 | 1,001 | 410 | 230 | 103 |
| 30 Sep 22 | 1,014 | 468 | 212 | 90 |
| 30 Jun 22 | 952 | 444 | 190 | 88 |
| 31 Mar 22 | 987 | 493 | 183 | 83 |
| 31 Dec 21 | 1,103 | 571 | 211 | 80 |
| 30 Sep 21 | 1,015 | 514 | 209 | 75 |
| 30 Jun 21 | 1,033 | 551 | 210 | 72 |
| 31 Mar 21 | 987 | 524 | 200 | 68 |
| 31 Dec 20 | 843 | 448 | 160 | 59 |
| 30 Sep 20 | 723 | 371 | 155 | 52 |
| 30 Jun 20 | 576 | 271 | 131 | 45 |
| 31 Mar 20 | 539 | 258 | 124 | 45 |
| 31 Dec 19 | 508 | 243 | 124 | 47 |
| 31 Dec 18 | 735 | 389 | 153 | 48 |
| 31 Dec 17 | 633 | 320 | 115 | 53 |
| 31 Dec 16 | 390 | 186 | 75 | 22 |
Kwaliteitswinsten: 688526 has high quality earnings.
Groeiende winstmarge: 688526's current net profit margins (33.2%) are lower than last year (42.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 688526's earnings have grown by 1.4% per year over the past 5 years.
Versnelling van de groei: 688526's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 688526 had negative earnings growth (-38.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
Rendement op eigen vermogen
Hoge ROE: 688526's Return on Equity (7.7%) is considered low.